News Archive 2006
ASHBURN, Va., November 9, 2006 /PRNewswire/ – Innocoll, Inc. announced that it has filed an Investigational New Drug (IND) application for its CollaRx™ GENTAMICIN as a topical antibiotic treatment for diabetic foot ulcers that are clinically infected or at risk of infection. CollaRx GENTAMICIN is a biodegradable and fully resorbable Gentamicin Collagen Sponge formulated and manufactured using Innocoll’s proprietary CollaRx technology.
Innocoll Announces Investigational New Drug Application Filing for its CollaRx™ GENTAMICIN as a Topical Treatment for Infected Diabetic Foot Ulcers.
ASHBURN, Va., October 12, 2006 /PRNewswire/ — Innocoll, Inc. announced that its wholly-owned subsidiary, Innocoll Pharmaceuticals, has received US 510k approval for CollaGUARD™, an advanced wound care product based on Innocoll’s proprietary CollaRx™ membrane technology. CollaGUARD is indicated for the management of superficial and deep wounds, including coverage of skin ulcers and temporary dermatoplasty in the case of lesion and burns. CollaGUARD has already received CE-mark approval for marketing in Europe.
Innocoll, Inc. Receives FDA Approval for CollaGUARD™, A Collagen-Based Advanced Wound Care Product
ASHBURN, Va., August 01, 2006 /PRNewswire/ – Innocoll, Inc. announced its sales and marketing subsidiary, Innocoll Pharmaceuticals Ltd., has recently signed a multi-country distribution agreement with BurnsAdler Pharmaceuticals Inc., for its CollaRx GENTAMICIN SURGICAL IMPLANT. The countries included in the arrangement are: Mexico, Argentina, Chile, Colombia, and a number of the Caribbean islands.
ASHBURN, Va., and Athlone, Ireland, April 26, 2006 /PRNewswire/ – Innocoll, Inc. announced its sales and marketing subsidiary, Innocoll Pharmaceuticals Ltd., has launched a new version of its CollaRx Gentamicin Surgical Implant that is specially designed for maximum convenience and ease of use in cardiac surgery.
Innocoll, Inc. announced its sales and marketing subsidiary, Innocoll Pharmaceuticals Ltd., has recently signed distribution arrangements for its CollaRx GENTAMICIN SURGICAL IMPLANT in Iraq, Iran, Syria, Kazakhstan, Azerbaijan, Georgia, Uzbekistan, Tajikistan and Turkmenistan.
ASHBURN, Va., Mar 30 /PRNewswire/ – Innocoll, Inc. announced its sales and marketing subsidiary, Innocoll Pharmaceuticals Ltd., has recently signed a distribution agreement for its CollaRx GENTAMICIN SURGICAL IMPLANT in the Russian Federation. The product is indicated for the treatment and prevention of post-operative acquired infection.
Innocoll, Inc. Announces Initiation of Phase IIA Clinical Study of Bupivacaine Collagen Sponge.
ASHBURN, Va. and Roscommon, Ireland, Mar. 28, 2006 /PRNewswire/ – Innocoll, Inc. announced today that its Drug Delivery Division, Innocoll Technologies Ltd., has initiated a Phase IIA Clinical Study on the Bupivacaine Collagen Sponge under development for the management of post-operative pain following moderate/major abdominal, gynecological, thoracic or orthopedic surgeries
Innocoll Announces Approval to Promote its CollaRx GENTAMICIN SURGICAL IMPLANT in Norway
ASHBURN, Va., Mar. 7, 2006 /PRNewswire/ – Innocoll, Inc. announced its sales and marketing subsidiary, Innocoll Pharmaceuticals Ltd., has obtained approval to promote its GENTAMICIN SURGICAL IMPLANT in Norway. Previously, the product was available on a named patient basis only in Norway.